Abstract
The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. In this retrospective study, we used the methylation-specific polymerase chain reaction to investigate MGMT promoter methylation status and immunohistochemistry to evaluate MGMT expression in patients with DLBCL who received rituximab plus CHOP (R-CHOP) chemotherapy. No difference in patient characteristics, disease characteristics, response, or survival in patients with DLBCL who received front-line R-CHOP chemotherapy was observed according to MGMT methylation status and MGMT expression. On multivariate analysis, Grade 3-4 mucositis in the MGMT methylated group was significantly higher than that in the MGMT unmethylated group (hazard ratio (HR) 2.40, 95% CIs: 1.26-7.26, p = 0.014). This study demonstrated that inactivation of MGMT does not appear to play an important role in patients with DLBCL who received R-CHOP chemotherapy either with regard to the response rate or overall survival. Additionally, Grade 3-4 mucositis was found to be significantly related with inactivation of MGMT by a multivariate analysis.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
DNA Methylation
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Humans
-
Immunohistochemistry
-
Lymphoma, Large B-Cell, Diffuse / diagnosis
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / enzymology
-
Male
-
Middle Aged
-
Mucositis / chemically induced
-
Multivariate Analysis
-
O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors*
-
O(6)-Methylguanine-DNA Methyltransferase / genetics
-
O(6)-Methylguanine-DNA Methyltransferase / metabolism
-
Polymerase Chain Reaction / methods
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Prognosis
-
Promoter Regions, Genetic / genetics
-
Retrospective Studies
-
Rituximab
-
Survival Analysis
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
O(6)-Methylguanine-DNA Methyltransferase
-
Prednisone